BRAF-Related In Vivo Models
Discover our comprehensive platform of CDX and PDX tumor models, carrying BRAF mutations across multiple cancer types:
- 18 CDX models carrying BRAF mutation (V600E, G469A, G464V, G466V, G596R or N581Y), covering melanoma, breast cancer, lung cancer and colorectal cancer
- 18 PDX models carrying BRAF mutation (V600E, G469A, G469E, D594N or N581S), covering melanoma, pancreatic cancer, lung cancer, head & neck cancer, colorectal cancer and lymphoma
- Case studies of BRAF and MEK inhibitor evaluation in tumor models carrying Class I, II or III BRAF mutations
BRAF related in vivo models-OncoWuXi Newsletter
Related Content
Mutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug,...
VIEW RESOURCEWith advancements in drug design, there is resurging interest in drugs that form covalent bonds with their targets, often referred...
VIEW RESOURCE